drugset / Trial / NCT02772497

3 Month Outcome of Ziv-aflibercept for DME

NCT02772497

Phase 2/3 Completed 10 enrolled Marashi Eye Clinic
NaSingle-groupOpen-labelTreatment

Summary

The purpose is to show the 3-month efficacy and safety in diabetic macular edema treated with intravitreal ziv-aflibercept.

Timeline

Start
2016-01
Primary completion
2016-05
Completion
2016-05

Publications

  • Results Marashi A (2016) Three-Month Outcome of Ziv-Aflibercept for Diabetic Macular Edema. Adv Ophthalmol Vis Syst 4(3): 00114. DOI: 10.15406/aovs.2016.04.00114

Drugs

EvaluationDrugModalityDoseRoute
Subject Aflibercept Protein / enzyme biologic 1.25 mg Intravitreal